Neuralstem Inc., the tiny Rockville biotech whose human stem cells have helped paralyzed rats walk again, is poised to launch its first trials on severe spinal cord conditions in humans.
The 11-year-old company is finally readying for trials of its patented nerve stem cell products on the first three of its possible targets: traumatic spinal cord injury; another type of paralysis often associated with stroke; and amyotrophic lateral sclerosis, known as Lou Gehrig’s disease. There are no cures for the conditions.
In a study at Johns Hopkins, Neuralstem stem cells extended the life of rats with a form of ALS. Continue Reading »